How India Exports Fluticasone to the World

In the United States, fluticasone products are subject to the Food and Drug Administration's (FDA) rigorous approval processes. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for fluticasone, indicating a competitive generic market. Recent approvals include:

- Fluticasone Propionate Nasal Spray: Approved in March 2025.

- Fluticasone Furoate Inhalation Powder: Approved in June 2025.

These approvals reflect the FDA's ongoing evaluation and authorization of fluticasone formulations. Notably, there are no current import alerts related to fluticasone, suggesting compliance with FDA standards among exporters. Given the presence of 239 active Indian exporters, adherence to the FDA's stringent regulatory requirements is imperative for market access.

In the European Union (EU) and the United Kingdom (UK), fluticasone-containing products require marketing authorization from the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. For instance, the EMA granted marketing authorization for Avamys (fluticasone furoate) on January 11, 2008, for the treatment of allergic rhinitis. Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines to ensure product quality and safety.

Fluticasone is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also subject to standards set forth in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, fluticasone is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for fluticasone-containing formulations, with the latest revision in September 2025. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for fluticasone have expired, leading to increased generic competition globally. This has facilitated the entry of multiple manufacturers into the market, contributing to the availability and affordability of fluticasone products.

In the past 12 months, several notable developments have occurred:

- April 2025: The EMA withdrew the marketing authorization for Airexar Spiromax (salmeterol/fluticasone propionate) at the request of the marketing authorization holder, Teva B.V., due to commercial reasons. (ema.europa.eu)

- June 2025: The FDA approved a new generic version of fluticasone propionate nasal spray, expanding treatment options for allergic rhinitis.

- September 2025: The NPPA revised the ceiling price for fluticasone-containing formulations, reflecting changes in market dynamics and cost structures.

These developments highlight the dynamic nature of the pharmaceutical industry and the importance of staying abreast of regulatory changes and market trends.

Fluticasone, a corticosteroid used in various respiratory treatments, relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) for its production. India, a major exporter of Fluticasone, sources a significant portion of these critical components from China. According to a 2025 report by the U.S. Pharmacopeia, 41% of KSMs used for U.S.-approved APIs are solely sourced from China, highlighting a substantial dependency. This reliance exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or environmental regulations affecting Chinese manufacturing.

The COVID-19 pandemic underscored the vulnerabilities associated with this dependency. During the crisis, Chinese factory shutdowns led to immediate shortages and price surges for essential APIs, including those used in Fluticasone production. This situation prompted the Indian government to initiate the Production Linked Incentive (PLI) scheme in February 2021, aiming to bolster domestic API and KSM manufacturing. Despite these efforts, as of November 2024, India's import dependence on key pharmaceutical ingredients from China remained significant, with imports accounting for 43.45% of India's pharmaceutical imports, amounting to $3.6 billion.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration in Fluticasone exports from India. The top five exporters account for 95.9% of the total export value, with CIPLA LIMITED alone contributing $184.7 million, representing a 91.0% share. This heavy reliance on a single supplier poses significant risks, including potential supply disruptions due to operational issues, regulatory actions, or strategic shifts within the company.

The Indian government's PLI scheme, launched in February 2021, aims to reduce such dependencies by incentivizing domestic production of APIs and KSMs. While the scheme has led to the establishment of new manufacturing units, the impact on reducing supplier concentration in Fluticasone exports remains limited. As of November 2024, India's import dependence on key pharmaceutical ingredients from China remained significant, with imports accounting for 43.45% of India's pharmaceutical imports, amounting to $3.6 billion.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. Key maritime routes such as the Red Sea and the Strait of Hormuz are critical for transporting raw materials and finished products. Any instability in these regions can lead to delays and increased costs. Additionally, ongoing U.S.-China trade tensions have the potential to impact the availability and pricing of APIs and KSMs sourced from China.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various medications in recent years, often attributing them to supply chain disruptions. For instance, in February 2025, the FDA issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP), highlighting ongoing quality concerns and the potential for supply interruptions.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in local manufacturing capabilities for critical components.

• Strengthen Quality Assurance: Implement robust quality control measures to ensure compliance with international standards, mitigating risks associated with regulatory actions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain.

• Develop Contingency Plans: Create comprehensive risk management strategies, including alternative shipping routes and emergency stockpiles, to address potential disruptions.

RISK_LEVEL: HIGH